Table 2: Potential Therapeutic targets for extranodal NKTCL.

PathwaysGenesExpressionChromosomal locationReferences

EBVLMP2-TRUpN.A.[32]

Survival/apoptosis
CCND3Down6p21.1[69]
SERPINB9Down6p25[19, 57]
FASLUp1q23[60, 78]
TNFAIP3Down6q23[69, 79]

Cell signaling pathways
JAK-STATSTAT3Up17q21[80, 81]
JAK2Up9p24[69, 81]
IL10Up1q31-q32[81, 82]
AKTAKT1/2/3Up14q32.3/19q13.1/1q44[69, 70]
NOTCHNOTCH1Up9q34.3[24, 83]
WNTβ-CATENINUp3p22–p21.3[24, 69]
PDGFPDGFRAUp4q11–q13[69]
PDGFA/BUp7p22/22q12.3–q13.1[69]

Angiogenesis
HGFR (MET)Up7q31[78]
VEGFR2Up4q12[24, 69]
VEGFAUp6q12[24, 69]
HIF1αUp14q21–q24[24, 70, 84]

Tumor suppressor genes
del6q21PRDM1Down6q21–q22.1[70]
ATG5Down6q21[70]
AIM1Down6q21[70]
HACE1Down6q21[69, 85]

Other pathways/genes
TP53Down17p13.1[86, 87]
TP73Down1p36.3[88]
AURKAUp20q13[24, 89]

N.A.: not applicable.